J. William Freytag, PH.D. appointed Chairman and Chief Executive Officer of Aspreva Pharmaceuticals

Press Release- Victoria, B.C July 11, 2007- Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced the appointment of Dr. J. William Freytag, 55, as Chairman and Chief Executive Officer, succeeding Richard Glickman, effective immediately. Mr. Glickman, one of Aspreva’s founders and the company’s first Chairman and CEO, had announced in May 2007 his planned departure from Aspreva.

As Aspreva’s new Chairman and CEO, Dr. Freytag brings tremendous experience in the biotechnology and pharmaceutical industries. Most recently Dr. Freytag served as President, CEO and Chairman of Myogen, Inc., a publicly-traded development-stage biopharmaceutical company, which was acquired by Gilead Sciences in 2006. Prior to Myogen, Dr. Freytag served as Senior Vice President, Technology and Business Development at Somatogen, Inc., and President, Molecular Diagnostics at Boehringer Mannheim Corporation. He also held senior positions in the areas of business operations, strategic planning and business development within the Medical Products Department of E.I. DuPont de Nemours & Co.

"Bill brings substantial knowledge, expertise and experience to Aspreva, and we are fortunate to attract a leader with his outstanding record of accomplishments," said George Milne, lead director of Aspreva Pharmaceuticals. "We also thank Richard for his role in building Aspreva into the company it is today and wish him every success in the future. Aspreva has a world-class management team in place, and with a strong financial position and global clinical and regulatory capabilities, we believe the company is well-positioned for future growth. I am confident that Bill and the team at Aspreva will continue to build on the achievements of the company to establish Aspreva as a leading force in serving patients living with less common diseases."

Dr. Freytag currently serves on the Board of Directors for Immunicon Corporation, ARCA Discovery, Inc. and the Colorado BioScience Association, is a member of the Board of Advisors to the Colorado University Cardiovascular Institute, and serves on the Executive Advisory Council for the Bard Center for Entrepreneurship. Dr. Freytag previously served as Chairman of the Board of Directors for BioStratum, Inc., and served on the Boards of Ischemia Technologies, Inc., Hemosphere, Inc. and LDA Systems. He was also a member of the President’s Council of Advisors for Purdue University, and a founder and member of the Board of Directors of the Indiana Health Industry Forum.

Dr. Freytag received a Ph.D. from the University of Kansas Medical Center, and a B.S. in Biochemistry from Purdue University. He also completed a postdoctoral fellowship at the Duke University Medical Center.

About Aspreva Pharmaceuticals

Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV". Learn more at www.aspreva.com.